Department of Orthopaedics, Dongguan Tungwah Hospital, Dongguan, Guangdong, China.
Department of Pulmonary and Critical Care Medicine, Dongguan Tungwah Hospital, Dongguan, Guangdong, China.
Front Endocrinol (Lausanne). 2022 Oct 27;13:1047433. doi: 10.3389/fendo.2022.1047433. eCollection 2022.
Glycolytic metabolic pathway has been confirmed to play a vital role in the proliferation, survival, and migration of malignant tumors, but the relationship between glycolytic pathway-related genes and osteosarcoma (OS) metastasis and prognosis remain unclear.
We performed Gene set enrichment analysis (GSEA) on the osteosarcoma dataset in the TARGET database to explore differences in glycolysis-related pathway gene sets between primary osteosarcoma (without other organ metastases) and metastatic osteosarcoma patient samples, as well as glycolytic pathway gene set gene difference analysis. Then, we extracted OS data from the TCGA database and used Cox proportional risk regression to identify prognosis-associated glycolytic genes to establish a risk model. Further, the validity of the risk model was confirmed using the GEO database dataset. Finally, we further screened OS metastasis-related genes based on machine learning. We selected the genes with the highest clinical metastasis-related importance as representative genes for experimental validation.
Using the TARGET osteosarcoma dataset, we identified 5 glycolysis-related pathway gene sets that were significantly different in metastatic and non-metastatic osteosarcoma patient samples and identified 29 prognostically relevant genes. Next, we used multivariate Cox regression to determine the inclusion of 13 genes (ADH5, DCN, G6PD, etc.) to construct a prognostic risk score model to predict 1- (AUC=0.959), 3- (AUC=0.899), and 5-year (AUC=0.895) survival under the curve. Ultimately, the KM curves pooled into the datasets GSE21257 and GSE39055 also confirmed the validity of the prognostic risk model, with a statistically significant difference in overall survival between the low- and high-risk groups (P<0.05). In addition, machine learning identified INSR as the gene with the highest importance for OS metastasis, and the transwell assay verified that INSR significantly promoted OS cell metastasis.
A risk model based on seven glycolytic genes (INSR, FAM162A, GLCE, ADH5, G6PD, SDC3, HS2ST1) can effectively evaluate the prognosis of osteosarcoma, and experiments also confirmed the important role of INSR in promoting OS migration.
糖酵解代谢途径已被证实对恶性肿瘤的增殖、存活和迁移起着至关重要的作用,但糖酵解途径相关基因与骨肉瘤(OS)转移和预后之间的关系仍不清楚。
我们在 TARGET 数据库中的骨肉瘤数据集上进行了基因集富集分析(GSEA),以探讨原发性骨肉瘤(无其他器官转移)和转移性骨肉瘤患者样本中糖酵解相关途径基因集之间的差异,以及糖酵解途径基因集基因差异分析。然后,我们从 TCGA 数据库中提取 OS 数据,并使用 Cox 比例风险回归来识别与预后相关的糖酵解基因,以建立风险模型。进一步,使用 GEO 数据库数据集验证风险模型的有效性。最后,我们基于机器学习进一步筛选与 OS 转移相关的基因。我们选择了与临床转移相关性最重要的基因作为代表基因进行实验验证。
使用 TARGET 骨肉瘤数据集,我们鉴定出 5 个在转移性和非转移性骨肉瘤患者样本中存在显著差异的糖酵解相关途径基因集,并鉴定出 29 个与预后相关的基因。接下来,我们使用多变量 Cox 回归确定包含 13 个基因(ADH5、DCN、G6PD 等)的纳入以构建预测 1-(AUC=0.959)、3-(AUC=0.899)和 5 年(AUC=0.895)生存曲线的预后风险评分模型。最终,汇集到数据集 GSE21257 和 GSE39055 的 KM 曲线也证实了预后风险模型的有效性,低风险组和高风险组之间的总生存率存在统计学差异(P<0.05)。此外,机器学习确定 INSR 是骨肉瘤转移最重要的基因,Transwell 检测证实 INSR 显著促进了 OS 细胞的转移。
基于 7 个糖酵解基因(INSR、FAM162A、GLCE、ADH5、G6PD、SDC3、HS2ST1)的风险模型可以有效地评估骨肉瘤的预后,并且实验还证实了 INSR 在促进 OS 迁移中的重要作用。